Radioactive seeds interstitial implantation for stage Ⅳ pancreatic cancer
10.3760/cma.j.issn.115807-20200608-00175
- VernacularTitle:经皮穿刺 125I放射性粒子组织间植入治疗Ⅳ期胰腺癌
- Author:
Wentao YANG
1
;
Qingchun LI
;
Xianbin CHENG
;
Pu SHAO
;
Qianqian WANG
;
Baodong GAI
Author Information
1. 吉林大学白求恩第三医院胃肠结直肠肛门外科，长春 130033
- From:
Chinese Journal of Endocrine Surgery
2020;14(3):181-184
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To identify the significance of interstitial implantation of radioactive seeds for stage IV pancreatic cancer.Methods:Clinical and follow-up data of 37 patients of stage Ⅳ pancreatic cancer with ultrasound-guided percutaneous radioactive seeds implantation as the primary treatment were retrospectively analyzed.Results:The postoperative survival time of 37 cases in the whole group was (7.49±4.08) months, ranging from 3 to17 months. Of the 30 patients who had upper abdominal and/or back pain before operation, 27 patients got different degrees of pain relief after operation; 20 cases were found with ascites before operation, but ascites in 18 cases decreased or disappeared after operation.Conclusion:The treatment of interstitial implantation of 125I radioactive seeds can effectively upgrade the life quality of stage IV pancreatic cancer patients.
